Eleanor Ager
About Eleanor Ager
Eleanor Ager is the Medical Lead for Gastrointestinal Cancers at Bristol Myers Squibb in Melbourne, Victoria, Australia, with extensive experience in oncology research and drug development.
Title and Current Position
Eleanor Ager holds the position of Medical Lead for Gastrointestinal Cancers at Bristol Myers Squibb. She is based in Melbourne, Victoria, Australia, where she focuses on medical leadership in the field of gastrointestinal oncology.
Previous Roles at Bristol Myers Squibb
Before her current role, Eleanor worked as the Associate Medical Lead for Immuno-Oncology from 2020 to 2021, and as a Medical Science Liaison from 2017 to 2020, both roles with Bristol Myers Squibb in Sydney, Australia. These positions involved providing internal scientific advice and liaising with the medical community on oncology projects.
Early Career and Post-Doctoral Research
Eleanor began her career with various research-focused roles. She worked at Novogen as Program Manager for Translational Biology from 2014 to 2017. Prior to that, she held several post-doctoral research fellow positions, including at The University of Melbourne and Massachusetts General Hospital/Harvard Medical School. Her research has been published in high-impact journals, and she has presented her findings at numerous scientific conferences.
Educational Background
Eleanor earned her Doctor of Philosophy (PhD) from the University of Melbourne, where she specialized in Genomic Imprinting in Placentation from 2003 to 2007. She also holds a Bachelor of Science (BSc) with Honors in Zoology and Molecular Genetics from The University of Western Australia, completed between 1997 and 2002.
Research and Expertise
Throughout her post-doctoral career, Eleanor has secured several research grants and developed new studies to advance the understanding of drug candidates and novel technology platforms. She specializes in preclinical and clinical research in oncology, including solid tumors and a variety of cancer types, as well as in signal transduction, immuno-oncology, epigenetics, cell and tumor biology, and biomarkers.